Guggenheim Downgrades Centessa Pharmaceuticals to Neutral

Benzinga Newsdesk www.benzinga.com Negative 90.8%

Neg 90.8% Neu 0% Pos 0%

Guggenheim analyst Debjit Chattopadhyay downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Buy to Neutral.

Comments

No comments yet. Be the first!